Financial Analysis: TriSalus Life Sciences (TLSI) versus The Competition

TriSalus Life Sciences (NASDAQ:TLSI) is one of 225 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare TriSalus Life Sciences to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, dividends and risk.

Analyst Recommendations

This is a summary of current ratings for TriSalus Life Sciences and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	4	0	3.00
TriSalus Life Sciences Competitors	1662	4404	8408	251	2.49

TriSalus Life Sciences presently has a consensus price target of $12.50, indicating a potential upside of 198.33%. As a group, “Surgical & medical instruments” companies have a potential upside of 17.60%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than its rivals.

Volatility & Risk

TriSalus Life Sciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences’ rivals have a beta of 0.53, meaning that their average share price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares TriSalus Life Sciences and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TriSalus Life Sciences	$24.74 million	-$59.04 million	-1.68
TriSalus Life Sciences Competitors	$875.84 million	$47.94 million	-1.12

TriSalus Life Sciences’ rivals have higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares TriSalus Life Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-219.71%	N/A	-192.99%
TriSalus Life Sciences Competitors	-575.50%	-141.13%	-25.81%

Insider & Institutional Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 47.4% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 76.2% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 15.9% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

TriSalus Life Sciences rivals beat TriSalus Life Sciences on 7 of the 13 factors compared.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.